KDM6A: A Potential Drug Target Or Biomarker for Diseases (G7403)

Target Name: KDM6A

NCBI ID: G7403

KDM6A: A Potential Drug Target Or Biomarker for Diseases

The KDM6A gene, located on the X chromosome, has been identified as a potential drug target or biomarker for several diseases. Its function in the body and its connection to human disease have been the focus of extensive research in recent years.

The KDM6A gene is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in the nucleus. It is a key regulator of the translation of the TPR gene, which encodes a protein involved in the treatment of various diseases. The TPR gene has been associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Research has shown that KDM6A is involved in the regulation of TPR gene expression and that its levels are often decreased in these diseases. This suggests that KDM6A may be a useful target for drugs that can increase TPR gene expression or inhibit its degradation.

One of the potential benefits of targeting KDM6A is its potential to treat diseases that are characterized by the over-expression of TPR genes. By increasing the levels of TPR genes, drugs can potentially lead to a reduction in the production of toxic proteins that are associated with these diseases.

Another potential benefit of KDM6A is its potential as a biomarker for disease diagnosis and monitoring. The TPR gene has been shown to be involved in the development and progression of several diseases, including cancer. By targeting KDM6A, researchers may be able to develop new diagnostic tests or monitoring tools for these diseases.

Targeting KDM6A has also been shown to have potential therapeutic applications in neurodegenerative diseases. The TPR gene has been associated with the development of several neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. By increasing the levels of TPR genes, drugs may potentially lead to a reduction in the production of toxic proteins that are associated with these diseases.

In conclusion, the KDM6A gene has the potential to be a drug target or biomarker for several diseases. Its role in the regulation of TPR gene expression and its connection to human disease make it an attractive target for researchers. Further research is needed to fully understand the potential therapeutic applications of KDM6A and to develop new treatments for diseases associated with its over-expression.

Protein Name: Lysine Demethylase 6A

Functions: Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code (PubMed:17851529, PubMed:17713478, PubMed:17761849). Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-27' (PubMed:17851529, PubMed:17713478, PubMed:17761849). Plays a central role in regulation of posterior development, by regulating HOX gene expression (PubMed:17851529). Demethylation of 'Lys-27' of histone H3 is concomitant with methylation of 'Lys-4' of histone H3, and regulates the recruitment of the PRC1 complex and monoubiquitination of histone H2A (PubMed:17761849). Plays a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression (By similarity)

More Common Targets